New nanosensor could unlock better mitochondrial disease diagnosis
NCT ID NCT04086329
First seen Sep 30, 2025 · Last updated May 12, 2026 · Updated 25 times
Summary
This early-phase study is testing a new, minimally invasive nanosensor that measures oxygen levels in muscle tissue. Researchers want to see if it can tell the difference between people with mitochondrial myopathy and healthy volunteers. The goal is to develop a reliable tool to track disease severity and response to future treatments. The study involves 24 adults aged 18-65 and includes a handgrip exercise test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL MYOPATHIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.